Influence of XPC, XPD, XPF, and XPG gene polymorphisms on the risk and the outcome of acute myeloid leukemia in a Romanian population

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
Claudia BănescuErzsebeth Lazar

Abstract

XPC, XPD, XPF, and XPG genes are implicated in the nucleotide excision repair (NER) system. Gene polymorphisms in NER repair system may influence the individual's capacity to recognize and repair DNA lesions, thus increasing the cancer risk. We hypothesized that these gene polymorphisms might influence the probability of developing acute myeloid leukemia (AML). We investigated the XPC, XPD, XPF, and XPG gene polymorphisms in 108 AML cases and 163 healthy controls. Also cytogenetic analyses besides FLT3 and DNMT3A mutations status were investigated. We found that variant genotypes (heterozygous and homozygous) of XPD 2251A > C and 22541A > C and the heterozygous genotype of XPG 3507G > C were associated with the risk of developing AML (OR = 2.55; 95% CI = 1.53-4.25; p value <0.001; OR = 1.66, 95 % CI = 1.02-2.72; p value = 0.047, and OR = 2.36; 95 % CI = 1.32-4.21; p value = 0.004, respectively). No association was found between white blood cell counts, FLT3, DNMT3A mutations, cytogenetic risk group, and variant genotypes of none of the analyzed polymorphisms. Variant homozygous XPF 673C > T genotype was associated with higher dose of cytosine arabinoside treatment administrated to AML patients (p value = 0.04). No differences w...Continue Reading

References

Aug 7, 2002·Current Oncology Reports·Claudia Schoch, Torsten Haferlach
Nov 19, 2002·Mutagenesis·Simone Benhamou, Alain Sarasin
Mar 20, 2008·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Fan WangYa-shuang Zhao
Jul 2, 2008·Haematologica·Konstanze Döhner, Hartmut Döhner
Mar 17, 2010·International Journal of Cancer. Journal International Du Cancer·Jing-Yi ShiSai-Juan Chen
Jun 25, 2010·American Journal of Hematology·Vicent M GuillemJuan-Carlos Hernández-Boluda
Sep 13, 2012·International Journal of Hematology·Peipei XuZuhong Lu

❮ Previous
Next ❯

Citations

May 4, 2016·Nucleic Acids Research·Alush I AvilaMartin D Burkhalter
May 2, 2019·Bioscience Reports·Yezhou LiuJinhai Jia
Aug 14, 2018·Frontiers in Genetics·Min WenXiaojiang Hao
Sep 28, 2020·Journal of Cancer Research and Clinical Oncology·Andrés Cardona-Echeverry, Jeanette Prada-Arismendy
Aug 28, 2021·Journal of Medical Case Reports·H BencharefA Quessar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.